BioNTech (NASDAQ:BNTX) Earns Buy Rating from Analysts at Berenberg Bank

Research analysts at Berenberg Bank initiated coverage on shares of BioNTech (NASDAQ:BNTX) in a report released on Tuesday, MarketBeat reports. The brokerage set a “buy” rating and a $130.00 price target on the stock. Berenberg Bank’s price target indicates a potential upside of 27.28% from the company’s current price.

A number of other brokerages also recently commented on BNTX. Morgan Stanley raised shares of BioNTech from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $93.00 to $145.00 in a research note on Tuesday, September 24th. TD Cowen dropped their price target on shares of BioNTech from $132.00 to $122.00 and set a “hold” rating on the stock in a research note on Tuesday, November 5th. HC Wainwright reaffirmed a “buy” rating and set a $150.00 price target on shares of BioNTech in a research note on Monday. Canaccord Genuity Group reaffirmed a “buy” rating and set a $171.00 price target on shares of BioNTech in a research note on Thursday, November 14th. Finally, HSBC lifted their price target on shares of BioNTech from $97.00 to $136.00 and gave the stock a “buy” rating in a research note on Monday, October 7th. Four analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $138.79.

BioNTech Stock Down 4.0 %

BNTX stock opened at $102.14 on Tuesday. The company’s 50 day simple moving average is $113.74 and its 200-day simple moving average is $97.49. The firm has a market capitalization of $24.49 billion, a PE ratio of -48.64 and a beta of 0.26. BioNTech has a 12 month low of $76.53 and a 12 month high of $131.49. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.26) by $2.07. The firm had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. BioNTech’s revenue was up 38.9% compared to the same quarter last year. During the same quarter last year, the business earned $0.73 earnings per share. Equities analysts expect that BioNTech will post -3.68 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioNTech

Several large investors have recently made changes to their positions in BNTX. Candriam S.C.A. grew its holdings in BioNTech by 261.2% during the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock valued at $46,526,000 after buying an additional 418,695 shares in the last quarter. Baillie Gifford & Co. lifted its position in BioNTech by 0.4% in the third quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company’s stock valued at $986,750,000 after purchasing an additional 31,773 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in BioNTech by 63.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 18,939 shares of the company’s stock valued at $2,249,000 after purchasing an additional 7,340 shares during the last quarter. Discovery Capital Management LLC CT purchased a new position in shares of BioNTech during the second quarter valued at approximately $2,467,000. Finally, Deerfield Management Company L.P. Series C grew its stake in BioNTech by 4.3% in the second quarter. Deerfield Management Company L.P. Series C now owns 594,000 shares of the company’s stock worth $47,734,000 after purchasing an additional 24,426 shares during the period. 15.52% of the stock is owned by hedge funds and other institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.